Fusion Antibodies plc (AIM: FAB)

Fusion Antibodies Cash Flow Statement

Financials in millions GBP. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Net Income	-1.63	-2.23	-2.6	-1.2	-2.9	-0.7
Depreciation & Amortization	0.16	0.22	0.37	0.75	0.71	0.62
Other Amortization	-	-	-	0	0	0
Stock-Based Compensation	0.09	0.09	0.04	0.02	0.02	0.08
Other Operating Activities	0.2	0.22	-0.13	-0.02	1.72	-0.34
Change in Accounts Receivable	-0.17	0.13	0.82	-0.08	-0.55	0.17
Change in Inventory	0.29	0.08	0.05	-0.11	-0.14	-0.1
Change in Accounts Payable	-0.12	-0.28	-0.3	0.31	0.01	0.1
Operating Cash Flow	-1.17	-1.77	-1.75	-0.33	-1.14	-0.16
Capital Expenditures	-0	-0	-0.11	-0.26	-0.37	-0.11
Other Investing Activities	0.01	0	0	0	0	0.01
Investing Cash Flow	0	0	-0.11	-0.26	-0.36	-0.1
Long-Term Debt Issued	-	-	0.07	-	0.01	-
Long-Term Debt Repaid	-	-0.03	-0.06	-0.16	-0.16	-0.17
Net Debt Issued (Repaid)	-0.02	-0.03	0.01	-0.16	-0.15	-0.17
Issuance of Common Stock	1.14	2.81	-	0.12	3.02	-
Other Financing Activities	-0	-0.01	-0	-0.01	-0.22	-0.01
Financing Cash Flow	1.12	2.77	0	-0.06	2.65	-0.18
Foreign Exchange Rate Adjustments	0	0	0.01	0.01	-	-
Net Cash Flow	-0.05	1	-1.85	-0.64	1.15	-0.45
Free Cash Flow	-1.17	-1.77	-1.87	-0.59	-1.5	-0.27
Free Cash Flow Margin	-65.04%	-155.90%	-64.39%	-12.25%	-36.04%	-6.91%
Free Cash Flow Per Share	-0.01	-0.03	-0.07	-0.02	-0.06	-0.01
Cash Interest Paid	0	0.01	0	0.01	0.02	0.01
Cash Income Tax Paid	-	-0.28	-0.13	-0.1	-0.07	-0.02
Levered Free Cash Flow	-0.59	-0.98	-1.05	-0.22	-1.17	0.08
Unlevered Free Cash Flow	-0.58	-0.98	-1.05	-0.22	-1.16	0.09
Change in Net Working Capital	-0.21	-0.15	-0.44	-0.1	0.75	-0.16

Source: S&P Capital IQ. Standard template. Financial Sources.